Business Wire

BURJEEL-MEDICAL-CITY

23.5.2023 16:25:25 CEST | Business Wire | Press release

Share
Burjeel Medical City Launches Advanced Gynecology Institute to Offer Complex Care Solutions for Women

Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages. The launch comes just months after the hospital joined hands with the globally renowned Franco-European Multidisciplinary Institute of Endometriosis Academy (IFEM Endo). Three specialized clinics of the hospital - Gynecological Oncology, IFEM Endo Middle East Clinic, and Complex Gynecology Care - will come under AGI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005817/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

H.E. Dr. Maitha Bint Salem Al Shamsi, Minister of State, UAE Government, inaugurating Advanced Gynecology Institute at Burjeel Medical City (Photo: AETOSWire)

Prof. Horace Roman, a renowned endometriosis surgeon and founding member of IFEM Endo, will be heading the institute. Dr. Benjamin Merlot, Consultant - Obstetrics and Gynecology and founding member of IFEM Endo, Dr. Sandesh Kade, Specialist - Obstetrics and Gynecology, Dr. Monica Chauhan, Specialist - Obstetrics & Gynecology, and Dr. Jafaru Abu, Consultant Gynecological Oncology Surgery, are other members of the team.

“The institute's launch is a significant milestone in women’s healthcare in the region. Women’s health needs are diverse and complex, requiring a holistic approach to ensure that each patient receives personalized care that meets her specific needs,” said Prof. Roman, adding that the expert team will also be involved in clinical research and training.

AGI possesses state-of-the-art surgical suites with the latest technology, allowing for advanced procedures such as laparoscopic and robotic surgeries. In addition to treating gynecological cancers, AGI focuses on preserving reproductive function in patients, and improving the quality of life for patients with advanced or recurrent gynecological malignancies. The institute also offers highly advanced minimally invasive surgeries for endometriosis.

“The institute showcases our commitment to excellence and cements our position as a leader in complex care. With a focus on specialized clinics, and personalized care, the institute is poised to make a significant impact on the healthcare sector in the UAE and beyond,” said Mr. John Sunil, CEO, Burjeel Holdings.

About Burjeel Medical City

Burjeel Medical City is a 400-bed multi-specialty hospital and quaternary care center located in Abu Dhabi, UAE. It offers high-quality specialized treatment and complex care in over 40 adult and pediatric specialties, aided by state-of-the-art medical technology and an international team of experts. Find more information at https://www.burjeelmedicalcity.com/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005817/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release

Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat

The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 10:00:00 CEST | Press release

Including Executives and Policymakers from the UK Government, NVIDIA, AWS, Tony Blair Institute, AstraZeneca and Virgin Atlantic The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead

MOVIVA® launch spotlight at ESGE Days 20267.5.2026 09:58:00 CEST | Press release

“Turn down the food noise” During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.”

Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 09:57:00 CEST | Press release

GBCI Europe Impact Report 2026 highlights that 53% of European real estate leaders prioritize resilience as a financial imperative. Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of t

Criteo Selects Navan to Modernize Global Travel Management7.5.2026 09:00:00 CEST | Press release

Global commerce intelligence platform delivers high employee satisfaction with Navan Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Gli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye